HeartFlow is a leader in revolutionizing precision heartcare, uniquely combining human ingenuity with advanced technology. Our HeartFlow Analysis is a non-invasive, personalized cardiac test for stable symptomatic patients with coronary artery disease (CAD), the #1 cause of death worldwide.
Starting with a standard coronary CT scan, the HeartFlow Analysis leverages artificial intelligence and highly trained analysts to create a digital 3D model of the patient’s coronary arteries. The interactive, color coded 3D model is provided via a secure online interface and enables physicians to better evaluate the impact a coronary blockage has on blood flow and determine the best treatment for patients.
The HeartFlow Analysis is covered by Medicare and most private commercial payers. To date, nearly 100,000 patients worldwide have received a HeartFlow Analysis.
Learn more about the genesis of HeartFlow from our co-founders and about the impact the HeartFlow Analysis is having on their practices from physicians around the world.
It took a coalition of cardiologists, radiologists, administrators and others at Prairie Heart Institute at HSHS St John’s Hospital to evaluate, implement and measure the impact of using the HeartFlow Analysis. The results have been positive for the patients, physicians and hospital. Hear why they adopted the HeartFlow Analysis and what has made their implementation so successful.
Coronary computed tomography angiography (CCTA) techniques have been proven to accurately diagnose the presence or absence of atherosclerotic heart disease. More recently, CCTA derived fractional flow reserve (FFRCT) has been shown to accurately define the physiologic significance of lesions identified on CCTA images. Accordingly, we now have a single non-invasive test that is rapid, accurate, low cost, requires low radiation exposure and answers the key questions needed to effectively manage patients with stable chest pain. Disruption is occurring. There is an abundant, and growing, body of scientific literature from around the world highlighting the power of CT techniques. In some regions outside the U.S. there has already been guideline-driven adoption of CT as an initial diagnostic strategy in carefully selected patients. In the U.S., multidisciplinary experts in the cardiovascular community continue to critically examine strategies. A new MedAxiom white paper explores opportunities using CCTA and FFRCT and how cardiovascular programs can leverage these technologies to achieve the Quadruple Aim. Download the white paper.
Coronary CT angiography (CCTA), a non-invasive diagnostic technique for detecting coronary artery disease, is disrupting traditional approaches to evaluating patients with suspected disease. The newer modality of fractional flow reserve derived from CT (FFRCT) significantly increases the value of CCTA by objectively defining the physiologic significance of lesions identified by CCTA. A new roadmap provides insights and tools to support the implementation and roll-out of a CCTA and FFRCT strategy for cardiovascular programs. Learn how to operationalize and prepare your program for these modalities and how to partner with radiology for CCTA. Plus, understand revenue cycle and economic considerations, and performance management structures. Download the roadmap.